Japan’s health ministry pharmaceutical board approved the country’s first abortion pill in 2023 C.E., marking a significant shift in reproductive rights for a country that had relied exclusively on surgical abortion long after most of the world made medication-based options available. The approved drug, MeFeego Pack — manufactured by British pharmaceutical company Linepharma — combines mifepristone and misoprostol, two medications the World Health Organization classifies as safe and effective and includes on its Essential Medicines List.
At a glance
- Abortion pill approval: Japan’s Ministry of Health, Labor and Welfare pharmaceutical board approved MeFeego Pack on Friday, April 21, 2023 C.E., with final sign-off then proceeding to the health minister.
- Mifepristone and misoprostol: Clinical trials in Japan showed that 93% of participants had a complete abortion within 24 hours when using the two-pill combination, which can be used within nine weeks of pregnancy.
- Surgical abortion alternatives: Before this approval, Japan offered only two surgical options — curettage, which the WHO has described as “obsolete” and less safe, and the evacuation method — making it one of the last developed nations without a medical alternative.
A long time coming
The gap between Japan and the rest of the world on this issue was wide. France approved mifepristone in 1988 C.E. The United States followed in 2000 C.E. By the time Japan’s pharmaceutical board voted in 2023 C.E., the medication had been in use in dozens of countries for a generation or more.
Japanese activists had pushed for approval for years, arguing the delay denied pregnant people access to a safer, less invasive option. The WHO has specifically called on health systems to move away from curettage — the scraping of uterine tissue with a metal instrument — describing it as painful and carrying greater risk than medication-based methods or vacuum aspiration.
The ministry opened a public comment period before voting, an unusual step that reflected the sensitivity of the issue in Japan. Medical professionals and advocates submitted responses through an online portal, adding public weight to a process that had long stalled.
What doctors and advocates said
The approval drew immediate celebration from Japan’s medical community. Obstetrician and gynecologist Kanako Inaba wrote on Twitter that the moment was an opportunity to expand sex education and raise awareness about contraceptive options — framing the approval not as an endpoint, but as an opening.
Other physicians were more measured. NPR reported that obstetrician Mihyon Song highlighted the structural barriers that remain in Japan’s abortion law, including a requirement that women obtain spousal consent before receiving an abortion. Advocates have long argued this provision strips women of the right to make decisions about their own bodies.
Under Japanese law, abortion is permitted only when pregnancy threatens physical health for bodily or economic reasons, or in cases of rape. The combination of narrow legal grounds and the spousal consent requirement means the approval of the pill, while historic, operates within a still-restrictive legal framework.
Why medication abortion matters globally
The timing of Japan’s approval carried resonance beyond its borders. It came less than a year after the U.S. Supreme Court overturned Roe v. Wade in 2022 C.E., eliminating the federal constitutional right to abortion in the United States and triggering a wave of state-level restrictions. The contrast was striking: one country was expanding access while another was contracting it.
Medication abortion — specifically the mifepristone-misoprostol combination — has become the dominant method of abortion in many countries precisely because it can be administered early, does not require surgical facilities, and has a strong safety profile. The WHO has consistently recommended it as a first-line option.
For Japan, the approval also signaled movement on a topic the country has historically treated with considerable caution. The ministry’s decision to seek public input, and the volume of professional response it received, suggested growing appetite for broader reproductive health reform.
Still, the spousal consent requirement and the narrow legal conditions for abortion in Japan remain real obstacles. Approving a pill is one step. Changing the conditions under which people can access it is another — and that work continues.
Read more
For more on this story, see: CNN
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Indigenous land rights win at COP30 covers 160 million hectares
- The Good News for Humankind archive on Japan
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
